NO301563B1 - Fremgangsmåte for bestemmelse av galaktose-defisiens, samt et diagnostisk sett til bruk ved fremgangsmåten - Google Patents

Fremgangsmåte for bestemmelse av galaktose-defisiens, samt et diagnostisk sett til bruk ved fremgangsmåten Download PDF

Info

Publication number: NO301563B1
Authority: NO; Norway
Prior art keywords: protein; igg; serum; determining; galactose
Prior art date: 1989-05-19

Application number

NO902158A

Other languages

English (en)

Norwegian (no)

Other versions

NO902158L (no

NO902158D0 (no

Inventor

Yuji Yamada

Toru Naraki

Atsushi Koide

Tsuguo Mizuochi

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-05-19

Filing date

1990-05-15

Publication date

1997-11-10

1990-05-15 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1990-05-15 Publication of NO902158D0 publication Critical patent/NO902158D0/no

1990-11-20 Publication of NO902158L publication Critical patent/NO902158L/no

1997-11-10 Publication of NO301563B1 publication Critical patent/NO301563B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 19
229930182830 galactose Natural products 0.000 title claims abstract description 18
230000007812 deficiency Effects 0.000 title claims abstract description 9
238000009007 Diagnostic Kit Methods 0.000 title claims description 6
210000002966 serum Anatomy 0.000 claims abstract description 28
108090001090 Lectins Proteins 0.000 claims abstract description 26
102000004856 Lectins Human genes 0.000 claims abstract description 26
239000002523 lectin Substances 0.000 claims abstract description 26
102000004169 proteins and genes Human genes 0.000 claims abstract description 20
108090000623 proteins and genes Proteins 0.000 claims abstract description 20
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 8
238000011161 development Methods 0.000 claims abstract description 6
101710120037 Toxin CcdB Proteins 0.000 claims abstract description 5
150000001720 carbohydrates Chemical group 0.000 claims description 22
238000006243 chemical reaction Methods 0.000 claims description 13
239000000243 solution Substances 0.000 claims description 13
239000012528 membrane Substances 0.000 claims description 11
108010062580 Concanavalin A Proteins 0.000 claims description 9
108010034897 lentil lectin Proteins 0.000 claims description 9
102000003992 Peroxidases Human genes 0.000 claims description 6
230000000903 blocking effect Effects 0.000 claims description 6
108040007629 peroxidase activity proteins Proteins 0.000 claims description 6
239000000758 substrate Substances 0.000 claims description 6
239000000020 Nitrocellulose Substances 0.000 claims description 5
229920001220 nitrocellulos Polymers 0.000 claims description 5
239000008363 phosphate buffer Substances 0.000 claims description 5
230000002950 deficient Effects 0.000 claims description 4
239000007983 Tris buffer Substances 0.000 claims description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 2
239000012089 stop solution Substances 0.000 claims description 2
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
239000000872 buffer Substances 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
201000010099 disease Diseases 0.000 description 6
239000000523 sample Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
239000000032 diagnostic agent Substances 0.000 description 5
229940039227 diagnostic agent Drugs 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
238000002372 labelling Methods 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
108090001008 Avidin Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000003556 assay Methods 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
108091008400 carbohydrate binding proteins Proteins 0.000 description 1
102000023852 carbohydrate binding proteins Human genes 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
229940098197 human immunoglobulin g Drugs 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
239000003550 marker Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Pathology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)
Veterinary Medicine (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Electrotherapy Devices (AREA)
Measuring And Recording Apparatus For Diagnosis (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Molds, Cores, And Manufacturing Methods Thereof (AREA)

NO902158A 1989-05-19 1990-05-15 Fremgangsmåte for bestemmelse av galaktose-defisiens, samt et diagnostisk sett til bruk ved fremgangsmåten NO301563B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP12617789		1989-05-19

Publications (3)

Publication Number	Publication Date
NO902158D0 NO902158D0 (no)	1990-05-15
NO902158L NO902158L (no)	1990-11-20
NO301563B1 true NO301563B1 (no)	1997-11-10

Family

ID=14928591

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO902158A NO301563B1 (no)	1989-05-19	1990-05-15	Fremgangsmåte for bestemmelse av galaktose-defisiens, samt et diagnostisk sett til bruk ved fremgangsmåten

Country Status (12)

Country	Link
EP (1)	EP0398292B1 (fr)
JP (1)	JP2945075B2 (fr)
KR (1)	KR920007202B1 (fr)
CN (1)	CN1036156C (fr)
AT (1)	ATE126598T1 (fr)
CA (1)	CA2016125A1 (fr)
DE (1)	DE69021631T2 (fr)
DK (1)	DK0398292T3 (fr)
ES (1)	ES2076254T3 (fr)
FI (1)	FI97649C (fr)
GR (1)	GR3017345T3 (fr)
NO (1)	NO301563B1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2133772A1 (fr) *	1993-11-19	1995-05-20	Yuji Yamada	Methode et reactif pour l'essai de glycoconjugues
JP3537535B2 (ja) *	1994-07-14	2004-06-14	株式会社中埜酢店	免疫グロブリンｇ結合糖鎖構造に基づく臨床検査方法
JP4542732B2 (ja) *	1999-06-02	2010-09-15	学校法人日本大学	慢性関節リウマチの判定法
GB2362211A (en) *	2000-05-08	2001-11-14	Leuven K U Res & Dev	Detecting circulating immune complexes using protein G
CN112924671A (zh) *	2021-01-28	2021-06-08	中国医学科学院北京协和医院	一种用于诊断类风湿关节炎合并肺间质纤维化的生物标志物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0058780B1 (fr) *	1981-02-19	1987-03-04	F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft	Procédé de détermination d'antigènes ou d'anticorps
US4617262A (en) *	1983-07-22	1986-10-14	Cooperbiomedical, Inc.	Assaying for circulating immune complexes with labeled protein A
US4659659A (en) *	1985-01-22	1987-04-21	Monsanto Company	Diagnostic method for diseases having an arthritic component
US4863874A (en) *	1986-07-11	1989-09-05	The United States Of America As Represented By The Secretary Of The Army	Method for detecting phosphatidylinositol through binding to Concanavalin A
GB8726271D0 (en) *	1987-11-10	1987-12-16	Univ London	Protein glycosylation assay

1990
- 1990-05-04 CA CA002016125A patent/CA2016125A1/fr not_active Abandoned
- 1990-05-09 FI FI902322A patent/FI97649C/fi not_active IP Right Cessation
- 1990-05-14 JP JP12376690A patent/JP2945075B2/ja not_active Expired - Fee Related
- 1990-05-15 NO NO902158A patent/NO301563B1/no not_active IP Right Cessation
- 1990-05-16 DK DK90109242.9T patent/DK0398292T3/da active
- 1990-05-16 AT AT90109242T patent/ATE126598T1/de not_active IP Right Cessation
- 1990-05-16 DE DE69021631T patent/DE69021631T2/de not_active Expired - Fee Related
- 1990-05-16 ES ES90109242T patent/ES2076254T3/es not_active Expired - Lifetime
- 1990-05-16 EP EP90109242A patent/EP0398292B1/fr not_active Expired - Lifetime
- 1990-05-19 CN CN90103723A patent/CN1036156C/zh not_active Expired - Fee Related
- 1990-05-19 KR KR1019900007225A patent/KR920007202B1/ko not_active Expired
1995
- 1995-09-08 GR GR950401869T patent/GR3017345T3/el unknown

Also Published As

Publication number	Publication date
DE69021631T2 (de)	1996-02-22
GR3017345T3 (en)	1995-12-31
KR900017608A (ko)	1990-12-19
JP2945075B2 (ja)	1999-09-06
EP0398292A2 (fr)	1990-11-22
DE69021631D1 (de)	1995-09-21
EP0398292A3 (fr)	1991-11-13
EP0398292B1 (fr)	1995-08-16
KR920007202B1 (ko)	1992-08-27
CN1047392A (zh)	1990-11-28
ATE126598T1 (de)	1995-09-15
CN1036156C (zh)	1997-10-15
ES2076254T3 (es)	1995-11-01
FI97649B (fi)	1996-10-15
CA2016125A1 (fr)	1990-11-19
FI902322A0 (fi)	1990-05-09
FI97649C (fi)	1997-01-27
JPH0373857A (ja)	1991-03-28
DK0398292T3 (da)	1995-09-25
NO902158L (no)	1990-11-20
NO902158D0 (no)	1990-05-15

Legal Events

Date	Code	Title	Description
2003-12-29	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN NOVEMBER 2003

Publication	Publication Date	Title
JP4621268B2 (ja)	2011-01-26	癌発生及び転移に関与するタンパク質の糖鎖変化を測定して癌を診断する方法及びそれを利用した診断キット
JP4290424B2 (ja)	2009-07-08	タンパク質ｅｓｍ−１を検出するためのキット及び前記キットを使用する検出方法
NO20110895A1 (no)	2012-12-24	Kompetitive S100A9 immunoanalyser
KR0126236B1 (ko)	1997-12-24	완전 세포에 적용할 수 있는 면역측정분석 키트 및 방법
US6242197B1 (en)	2001-06-05	Use of urinary trypsin inhibitor for the diagnosis of the onset of AIDS
NO301563B1 (no)	1997-11-10	Fremgangsmåte for bestemmelse av galaktose-defisiens, samt et diagnostisk sett til bruk ved fremgangsmåten
US12000841B2 (en)	2024-06-04	Diagnostic kits and methods configured to rapidly and non-invasively determine physiologic levels of galactose-deficient IgA1 (Gd-IgA1) in the subject of IgA nephropathy
JP4597132B2 (ja)	2010-12-15	クローン病抗体エピトープペプチド及びクローン病の検査試薬
EP0782863B1 (fr)	2003-06-11	Reactif anticorpal pour la detection des anevrismes dissequants de l'aorte et utilisation de ce reactif
EP1947460B1 (fr)	2012-05-30	Méthode pour mesurer ptx3 avec une haute précision
EP0662611A2 (fr)	1995-07-12	Méthode pour l'essai de glycoconjugates et réactif de celle-ci
JPS60249058A (ja)	1985-12-09	Ａｔｌウイルス抗体の測定方法および試薬
US8841084B2 (en)	2014-09-23	Methods for the detection and monitoring of acute myocardial infarction
Saile et al.	1991	Quantification of serum amyloid P by enzyme-linked immunosorbent assay
RU2197736C1 (ru)	2003-01-27	Реагент для иммуноферментного анализа и способ иммуноферментного тестирования специфических антител при описторхозе, вызываемом печеночной трематодой opisthorhis felineus
JPH09311132A (ja)	1997-12-02	ＩｇＡ腎症の診断法
JPH07104350B2 (ja)	1995-11-13	腫瘍、癌、前癌症状の検出用キット
WO1992014153A1 (fr)	1992-08-20	Utilisation de serums de reference dans des essais immunologiques visant a detecter des anticorps contre des mycobacteries
WO2006003209A1 (fr)	2006-01-12	Utilisation de l'utéroglobine comme marqueur dans les maladies oncologiques et infectieuses humaines
JP2726500C (fr)	1999-12-20